GlassScriptPhysician profile
Nathan Allen Williamson
NPI 1306393061
$14,884.61
in general payments reported to CMS, 2019-2025
45 companies · $3,292 in 2025
The $3,292 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,399 · 2022: $2,927 · 2023: $3,129 · 2024: $3,139 · 2025: $3,292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,445 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,444.60 |
| Education | $114.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,666.04 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,507.93 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $1,227.48 | 2021-2025 | |
| Novo Nordisk INC | $1,109.99 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $993.88 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $872.83 | 2021-2025 | |
| Amgen INC. | $853.05 | 2021-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $692.51 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $440.06 | 2021-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $399.54 | 2022-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $388.55 | 2021-2025 | |
| Amarin Pharma, INC. | $353.36 | 2021-2022 | |
| Abbott Laboratories | $340.77 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Biohaven Pharmaceutical Holding Company LTD. | $340.72 | 2022 | |
| Esperion Therapeutics, INC. | $266.38 | 2021-2022 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $266.27 | 2021-2024 | Veozah, Myrbetriq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $232.03 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $207.71 | 2021-2024 | Xarelto, Acclarent Navwire |
| Corium, LLC | $158.92 | 2022-2023 | Azstarys, Adlarity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.59 | 2021-2025 | Xifaxan, Trulance |
| Neurocrine Biosciences, INC. | $140.75 | 2022-2023 | Ingrezza |
| Merck Sharp & Dohme LLC | $133.83 | 2021-2023 | Belsomra, Verquvo |
| Medtronic, INC. | $105.23 | 2024 | Interstim |
| Axsome Therapeutics, INC. | $97.16 | 2024-2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $96.01 | 2024 | Voquezna |
| Exact Sciences Corporation | $87.41 | 2023-2025 | Cologuard Collection Kit |
| Procept Biorobotics Corporation | $80.35 | 2025 | |
| Novartis Pharmaceuticals Corporation | $63.43 | 2021-2023 | |
| Lundbeck LLC | $53.93 | 2022-2025 | Rexulti |
| Kyowa Kirin, INC. | $48.59 | 2021 | |
| Averitas Pharma INC. | $48.52 | 2023-2025 | Qutenza |
| Sumitomo Pharma America, INC. | $46.89 | 2024-2025 | Gemtesa |
| Almatica Pharma LLC | $45.44 | 2024 | Loreev Xr |
| Alfasigma USA, INC. | $43.99 | 2021-2022 | |
| Dexcom, INC. | $41.33 | 2024-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $40.32 | 2021 | |
| Dynavax Technologies Corporation | $40.06 | 2022-2025 | Heplisav-B |
| Horizon Therapeutics Plc | $34.83 | 2022 | |
| Antares Pharma, INC. | $32.74 | 2021-2024 | Xyosted |
| Teva Pharmaceuticals USA, INC. | $29.26 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.42 | 2021-2022 | |
| Beta Bionics, INC. | $19.43 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Idorsia Pharmaceuticals US INC | $19.20 | 2022 | |
| Genentech USA, INC. | $19.01 | 2021 | |
| Boston Scientific Corporation | $14.87 | 2023 | Watchman Access System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Williamson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.